amoxapine
Trade name: asendin
Approved
Sep 22, 1980
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 5 marketing orgs
Timeline
1980s
- Sep 22, 1980
Lederle — Earliest FDA Approval
- Sep 22, 1980
Lederle — NDA Secondary Org
- Sep 22, 1980
Lederle — NDA Organization
- Sep 22, 1980
American Cyanamid — NDA Secondary Org
1990s
- Jun 28, 1991
Upsher-Smith Laboratories — Marketing Organization
- Jun 28, 1991
Chartwell Pharmaceuticals — Marketing Organization
- Aug 28, 1992
Watson Pharmaceuticals — Marketing Organization
Indications
Mechanism of action
- Dopamine receptorANTAGONIST
Dopamine receptor antagonist
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
Approval history
- approvedSep 22, 1980
Chemistry & pharmacology
SMILES
ClC1=CC=C2OC3=CC=CC=C3N=C(N4CCNCC4)C2=C1- Mol. weight
- 313.781 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAmoxapine ↗
- NCATSR63VQ857OT ↗
- ChEMBLCHEMBL1113 ↗
Also known as
- 2-chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
- 2-chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
- amoxan
- amoxapin
- amoxapin
- amoxapina
- amoxapina
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapine
- amoxapinum
- amoxapinum
- amoxepine
- amoxepine
- asendin
- asendin
- asendin
- asendis
- asendis
- cl-67772
- cl-67772
- defanyl
- defanyl
- desmethylloxapin
- desmethylloxapin
- desmethylloxapine
- moxadil
Organizations
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Cyanamid | For profit | NDA2 | Sep 22, 1980 |
| Chartwell Pharmaceuticals | For profit | MKTG | Jun 28, 1991 |
| Lederle | For profit | NDA2 | Sep 22, 1980 |
| Lederle | For profit | NDA | Sep 22, 1980 |
| Upsher-Smith Laboratories | For profit | MKTG | Jun 28, 1991 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 28, 1992 |
| Watson Pharmaceuticals | For profit | SYN | May 11, 1989 |